{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:19:57Z","timestamp":1790871597158,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00203-025-04508-8","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T07:38:07Z","timestamp":1763624287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pretomanid for the treatment of drug resistant pulmonary tuberculosis: a comprehensive review"],"prefix":"10.1007","volume":"208","author":[{"given":"Roopendra","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagdeep Singh","family":"Sohal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay Vir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devendra Singh","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"1","key":"4508_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00359-7","volume":"4","author":"S Bagcchi","year":"2023","unstructured":"Bagcchi S (2023) WHO\u2019s global tuberculosis report 2022. Lancet Microbe 4(1):e20. https:\/\/doi.org\/10.1016\/S2666-5247(22)00359-7","journal-title":"Lancet Microbe"},{"issue":"2","key":"4508_CR3","doi-asserted-by":"publisher","DOI":"10.1099\/acmi.0.000740.v3","volume":"6","author":"TJ Bagratee","year":"2024","unstructured":"Bagratee TJ, Studholme DJ (2024) Targeted genome sequencing for tuberculosis drug susceptibility testing in South Africa: a proposed diagnostic pipeline. Access Microbiol 6(2):000740.v3. https:\/\/doi.org\/10.1099\/acmi.0.000740.v3","journal-title":"Access Microbiol"},{"issue":"6","key":"4508_CR4","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/jac\/dkac070","volume":"77","author":"A Bateson","year":"2022","unstructured":"Bateson A, Ortiz Canseco J, McHugh TD, Witney AA, Feuerriegel S, Merker M, Kohl TA, Utpatel C, Niemann S, Andres S, Kranzer K, Maurer FP, Ghodousi A, Borroni E, Cirillo DM, Wijkander M, Toro JC, Groenheit R, Werngren J, Machado D, Viveiros M, Warren RM, Sirgel F, Dippenaar A, K\u00f6ser CU, Sun E, Timm J (2022) Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid. J Antimicrob Chemother 77(6):1685\u20131693. https:\/\/doi.org\/10.1093\/jac\/dkac070","journal-title":"J Antimicrob Chemother"},{"issue":"20","key":"4508_CR5","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1056\/NEJMc1505196","volume":"373","author":"GV Bloemberg","year":"2015","unstructured":"Bloemberg GV, Keller PM, Stucki D, Trauner A, Borrell S, Latshang T, Coscoll\u00e1 M, R\u00f6mkens M, B\u00f6ttger EC (2015) Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med 373(20):1986\u20131988. https:\/\/doi.org\/10.1056\/NEJMc1505196","journal-title":"N Engl J Med"},{"key":"4508_CR6","unstructured":"Centers for Disease Control and Prevention. (2023). Clinical overview of drug-resistant tuberculosis disease. https:\/\/www.cdc.gov\/tb\/topic\/drtb\/default.htm"},{"issue":"3","key":"4508_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S1473-3099(24)00586-3","volume":"25","author":"RE Colman","year":"2025","unstructured":"Colman RE, Seifert M, De la Rossa A, Georghiou SB, Hoogland C, Uplekar S, Laurent S, Rodrigues C, Kambli P, Tukvadze N, Maghradze N, Omar SV, Joseph L, Suresh A, Rodwell TC (2025) Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows. Lancet Infect Dis 25(3):325\u2013334. https:\/\/doi.org\/10.1016\/S1473-3099(24)00586-3","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"4508_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Spigelman M, McHugh TD, Bateson A, Hunt R, Nix-TB Trial Team (2020) Treatment of highly drug-resistant pulmonary tuberculosis. New England J Med 382(10):893\u2013902. https:\/\/doi.org\/10.1056\/NEJMoa1901814","journal-title":"New England J Med"},{"issue":"9","key":"4508_CR9","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, ZeNix Trial Team (2022) Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis. New England J Med 387(9):810\u2013823. https:\/\/doi.org\/10.1056\/NEJMoa2119430","journal-title":"New England J Med"},{"issue":"1","key":"4508_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00504-2","volume":"10","author":"K Dheda","year":"2024","unstructured":"Dheda K, Mirzayev F, Cirillo DM, Udwadia Z, Dooley KE, Chang KC, Omar SV, Reuter A, Perumal T, Horsburgh CR Jr, Murray M, Lange C (2024) Multidrug-resistant tuberculosis. Nat Rev Dis Primers 10(1):22. https:\/\/doi.org\/10.1038\/s41572-024-00504-2","journal-title":"Nat Rev Dis Primers"},{"key":"4508_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2024.102568","volume":"149","author":"HA Djunaedy","year":"2024","unstructured":"Djunaedy HA, Febinia CA, Hamers RL, Baird K, Elyazar I, Thuong NT, Trimarsanto H, Malik SG, Thwaites G, van Crevel R, Alisjahbana B (2024) A description of lineage 1 Mycobacterium tuberculosis from Papua. Indonesia Tuberculosis 149:102568. https:\/\/doi.org\/10.1016\/j.tube.2024.102568","journal-title":"Indonesia Tuberculosis"},{"issue":"7","key":"4508_CR12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1164\/rccm.202208-1475OC","volume":"207","author":"KE Dooley","year":"2023","unstructured":"Dooley KE, Hendricks B, Gupte N, Barnes G, Narunsky K, Whitelaw C, Smit T, Ignatius EH, Friedman A, Dorman SE, Dawson R, Assessing Pretomanid for Tuberculosis (APT) Study Team (2023) Assessing pretomanid for tuberculosis (APT) a randomized phase 2 trial of pretomanid-containing regimens for drug-sensitive tuberculosis: 12-week results. Am J Respirat Crit Care Med 207(7):929\u2013935. https:\/\/doi.org\/10.1164\/rccm.202208-1475OC","journal-title":"Am J Respirat Crit Care Med"},{"issue":"1","key":"4508_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/jb.00326-24","volume":"206","author":"IE Eke","year":"2025","unstructured":"Eke IE, Abramovitch RB (2025) Functions of nitroreductases in mycobacterial physiology and drug susceptibility. J Bacteriol 206(1):e00326\u201324","journal-title":"J Bacteriol"},{"issue":"2","key":"4508_CR14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3390\/medicina58020188","volume":"58","author":"J Espinosa-Pereiro","year":"2022","unstructured":"Espinosa-Pereiro J, S\u00e1nchez-Montalv\u00e1 A, Aznar ML, Espiau M (2022) MDR tuberculosis treatment. Medicina (b Aires) 58(2):188. https:\/\/doi.org\/10.3390\/medicina58020188","journal-title":"Medicina (b Aires)"},{"key":"4508_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jgar.2022.09.006","volume":"31","author":"G Fekadu","year":"2022","unstructured":"Fekadu G, Tolossa T, Turi E, Bekele F, Fetensa G (2022) Pretomanid development and its clinical roles in treating tuberculosis. J Glob Antimicrob Resist 31:175\u2013184. https:\/\/doi.org\/10.1016\/j.jgar.2022.09.006","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"4508_CR16","doi-asserted-by":"publisher","first-page":"2001796","DOI":"10.1183\/13993003.01796-2020","volume":"57","author":"S Feuerriegel","year":"2021","unstructured":"Feuerriegel S, Kohl TA, Utpatel C, Andres S, Maurer FP, Heyckendorf J, Jou R, Niemann S, Merker M (2021) Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB. Eur Respir J 57(1):2001796. https:\/\/doi.org\/10.1183\/13993003.01796-2020","journal-title":"Eur Respir J"},{"issue":"1","key":"4508_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cmi.2021.08.007","volume":"28","author":"T Gils","year":"2022","unstructured":"Gils T, Lynen L, de Jong BC, Van Deun A, Decroo T (2022) Pretomanid for tuberculosis: a systematic review. Clin Microbiol Infect 28(1):31\u201342. https:\/\/doi.org\/10.1016\/j.cmi.2021.08.007","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"4508_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1056\/NEJMc2404644","volume":"392","author":"GA Goig","year":"2025","unstructured":"Goig GA, Loiseau C, Maghradze N, Mchedlishvili K, Avaliani T, Brites D, Borrell S, Aspindzelashvili R, Avaliani Z, Kipiani M, Tukvadze N, Jugheli L, Gagneux S (2025) Transmission as a key driver of resistance to the new tuberculosis drugs. N Engl J Med 392(1):97\u201399. https:\/\/doi.org\/10.1056\/NEJMc2404644","journal-title":"N Engl J Med"},{"issue":"1","key":"4508_CR19","doi-asserted-by":"publisher","first-page":"19431","DOI":"10.1038\/s41598-021-98970-1","volume":"11","author":"PJ G\u00f3mez-Gonz\u00e1lez","year":"2021","unstructured":"G\u00f3mez-Gonz\u00e1lez PJ, Perdigao J, Gomes P, Puyen ZM, Santos-Lazaro D, Napier G, Viveiros M, Portugal I, Campino S (2021) Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid. Sci Rep 11(1):19431. https:\/\/doi.org\/10.1038\/s41598-021-98970-1","journal-title":"Sci Rep"},{"key":"4508_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijtb.2025.02.019","author":"R Gopalaswamy","year":"2025","unstructured":"Gopalaswamy R, Subramanian B, Parthasarathy M, Padmapriyadarsini C, Shanmugam S (2025) Direct targeted next-generation sequencing for diagnosis of drug-resistant tuberculosis from clinical samples \u2013 an update. Indian J Tuberc. https:\/\/doi.org\/10.1016\/j.ijtb.2025.02.019","journal-title":"Indian J Tuberc"},{"issue":"3","key":"4508_CR21","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3201\/eid3003.231162","volume":"30","author":"G G\u00fcnther","year":"2024","unstructured":"G\u00fcnther G, Mhuulu L, Diergaardt A, Dreyer V, Moses M, Anyolo K, Hamunime N, Uusiku P, Katjitae I, Khaiseb S (2024) Bedaquiline resistance after effective treatment of multidrug-resistant tuberculosis. Namibia Emerging Infect Dis 30(3):568\u2013572. https:\/\/doi.org\/10.3201\/eid3003.231162","journal-title":"Namibia Emerging Infect Dis"},{"issue":"3","key":"4508_CR22","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/ciad618","volume":"78","author":"T Hasan","year":"2024","unstructured":"Hasan T, Medcalf E, Nyangwa BT, Egizi E, Berry C, Dodd M, du Cros P, Fielding K (2024) The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis. Clin Infect Dis 78(3):730\u2013741. https:\/\/doi.org\/10.1093\/cid\/ciad618","journal-title":"Clin Infect Dis"},{"issue":"9","key":"4508_CR23","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1128\/AAC.00715-15","volume":"59","author":"HL Haver","year":"2015","unstructured":"Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, Wintjens R, Bifani P (2015) Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 59(9):5316\u20135323. https:\/\/doi.org\/10.1128\/AAC.00715-15","journal-title":"Antimicrob Agents Chemother"},{"key":"4508_CR24","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.dib.2018.09.062","volume":"20","author":"N Ismail","year":"2018","unstructured":"Ismail N, Omar SV, Ismail NA, Peters RP (2018) Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis. Data Brief 20:1975\u20131983. https:\/\/doi.org\/10.1016\/j.dib.2018.09.062","journal-title":"Data Brief"},{"key":"4508_CR25","doi-asserted-by":"publisher","first-page":"1194923","DOI":"10.3389\/fimmu.2023.1194923","volume":"14","author":"YM Jacobo-Delgado","year":"2023","unstructured":"Jacobo-Delgado YM, Rodr\u00edguez-Carlos A, Serrano CJ, Rivas-Santiago B (2023) Mycobacterium tuberculosis cell-wall and antimicrobial peptides: a mission impossible? Front Immunol 14:1194923. https:\/\/doi.org\/10.3389\/fimmu.2023.1194923","journal-title":"Front Immunol"},{"issue":"16","key":"4508_CR26","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam SJ (2019) Pretomanid: first approval. Drugs 79(16):1797\u20131803. https:\/\/doi.org\/10.1007\/s40265-019-01207-9","journal-title":"Drugs"},{"issue":"3","key":"4508_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5588\/ijtldopen.25.0152","volume":"2","author":"L Kuksa","year":"2025","unstructured":"Kuksa L, Andrejak C, Haecker B, Bothamley G, Calcagno A, Cirillo DM, Duarte R, Fatima R, Ferlazzo G, Guglielmetti L, G\u00fcnther G, Hewison C, Horsburgh CR, J\u00e4ger T, Kalancha Y, Otto-Knapp R, Kranzer K, Lillebaek T, Marks G, Middelkoop K, Motta I, Rabinova V, Sommerfeld P, Tattevin P, Lange C (2025) Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy. IJTLD Open 2(3):117\u2013119. https:\/\/doi.org\/10.5588\/ijtldopen.25.0152","journal-title":"IJTLD Open"},{"issue":"9","key":"4508_CR28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00913-17","volume":"61","author":"SY Li","year":"2017","unstructured":"Li SY, Tasneen R, Tyagi S, Soni H, Converse PJ, Mdluli K, Nuermberger EL (2017) Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 61(9):e00913\u201317. https:\/\/doi.org\/10.1128\/AAC.00913-17","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4508_CR29","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/cpdd.898","volume":"10","author":"M Li","year":"2021","unstructured":"Li M, Saviolakis GA, El-Amin W, Makhene MK, Osborn B, Nedelman J, Everitt D (2021) Phase 1 study of the effects of the tuberculosis treatment pretomanid, alone and in combination with moxifloxacin, on the QTc interval in healthy volunteers. Clin Pharmacol Drug Dev 10(6):634\u2013646. https:\/\/doi.org\/10.1002\/cpdd.898","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"4508_CR30","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1073\/pnas.0508392103","volume":"103","author":"UH Manjunatha","year":"2006","unstructured":"Manjunatha UH, Boshoff H, Dowd CS, Zhang L, Albert TJ, Norton JE, Daniels L, Dick T, Pang SS, Barry CE (2006) Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 103(2):431\u2013436. https:\/\/doi.org\/10.1073\/pnas.0508392103","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4508_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5588\/ijtld.22.0138","volume":"27","author":"H Mansoor","year":"2023","unstructured":"Mansoor H, Hirani N, Chavan V, Das M, Sharma J, Bharati M, Oswal V, Iyer A, Morales M, Joshi A, Ferlazzo G, Isaakidis P, Ndlovu Z, England K (2023) Clinical utility of target-based next-generation sequencing for drug-resistant TB. Int J Tuberc Lung Dis 27(1):41\u201348. https:\/\/doi.org\/10.5588\/ijtld.22.0138","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"4508_CR32","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1093\/jac\/dkad252","volume":"78","author":"S Mok","year":"2023","unstructured":"Mok S, Roycroft E, Flanagan PR, Wagener J, Fitzgibbon MM (2023) Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates. J Antimicrob Chemother 78(11):2637\u20132644. https:\/\/doi.org\/10.1093\/jac\/dkad252","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"4508_CR33","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/jac\/dkab505","volume":"77","author":"SE Mudde","year":"2022","unstructured":"Mudde SE, Upton AM, Lenaerts A, Bax HI, De Steenwinkel JEM (2022) Delamanid or pretomanid? A solomonic judgement! J Antimicrob Chemother 77(4):880\u2013902. https:\/\/doi.org\/10.1093\/jac\/dkab505","journal-title":"J Antimicrob Chemother"},{"key":"4508_CR34","unstructured":"National guidelines for management of drug-resistant tuberculosis. (2025). https:\/\/tbcindia.mohfw.gov.in\/wp-content\/uploads\/2025\/01\/National-Guidelines-for-Management-of-DR-TB_Final.pdf"},{"key":"4508_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2021.104802","volume":"91","author":"T Netikul","year":"2021","unstructured":"Netikul T, Palittapongarnpim P, Thawornwattana Y, Plitphonganphim S (2021) Estimation of the global burden of Mycobacterium tuberculosis lineage 1. Infect Genet Evol 91:104802. https:\/\/doi.org\/10.1016\/j.meegid.2021.104802","journal-title":"Infect Genet Evol"},{"issue":"4","key":"4508_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106953","volume":"62","author":"TV Nguyen","year":"2023","unstructured":"Nguyen TV, Nguyen QH, Nguyen TN, Anthony RM, Vu DH, Alffenaar JW (2023) Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice. Int J Antimicrob Agents 62(4):106953. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106953","journal-title":"Int J Antimicrob Agents"},{"key":"4508_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100128","volume":"3","author":"S Occhineri","year":"2022","unstructured":"Occhineri S, Matucci T, Rindi L, Tiseo G, Falcone M, Riccardi N, Goletti D (2022) Pretomanid for tuberculosis treatment: an update for clinical purposes. Curr Res Pharmacol Drug Discov 3:100128. https:\/\/doi.org\/10.1016\/j.crphar.2022.100128","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"1","key":"4508_CR38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ijtb.2020.09.005","volume":"68","author":"U Parveen","year":"2021","unstructured":"Parveen U, Sultana S, Heba SF, Rafi R, Begum A, Fatima N (2021) Pretomanid: a novel therapeutic paradigm for treatment of drug resistant tuberculosis. Indian J Tuberc 68(1):106\u2013113. https:\/\/doi.org\/10.1016\/j.ijtb.2020.09.005","journal-title":"Indian J Tuberc"},{"issue":"1","key":"4508_CR39","first-page":"3","volume":"74","author":"M Pstragowski","year":"2017","unstructured":"Pstragowski M, Zbrzezna M, Bujalska-Zadrozny M (2017) Advances in pharmacotherapy of tuberculosis. Acta Pol Pharm 74(1):3\u201311","journal-title":"Acta Pol Pharm"},{"issue":"1","key":"4508_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01948-20","volume":"65","author":"D Rifat","year":"2020","unstructured":"Rifat D, Li SY, Ioerger T, Shah K, Lanoix JP, Lee J, Bashiri G, Sacchettini J, Nuermberger E (2020) Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis. Antimicrob Agents Chemother 65(1):e01948\u201320. https:\/\/doi.org\/10.1128\/AAC.01948-20","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"4508_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00070-24","volume":"12","author":"P Rupasinghe","year":"2024","unstructured":"Rupasinghe P, Reenaers R, Vereecken J, Mulders W, Cogneau S, Merker M, Niemann S, Vally Omar S, Rigouts L, K\u00f6ser CU, Decroo T, de Jong BC (2024) Refined understanding of the impact of the Mycobacterium tuberculosis complex diversity on the intrinsic susceptibility to pretomanid. Microbiol Spectr 12(3):e0007024. https:\/\/doi.org\/10.1128\/spectrum.00070-24","journal-title":"Microbiol Spectr"},{"issue":"10","key":"4508_CR42","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/S1473-3099(24)00263-9","volume":"24","author":"TC Schwab","year":"2024","unstructured":"Schwab TC, Perrig L, G\u00f6ller PC, Guebely De la Hoz FF, Lahousse AP, Minder B, G\u00fcnther G, Efthimiou O, Omar SV, Egger M, Fenner L (2024) Targeted next-generation sequencing to diagnose drug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 24(10):1162\u20131176","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"4508_CR43","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01390-24","volume":"63","author":"TC Schwab","year":"2025","unstructured":"Schwab TC, Joseph L, Moono A, G\u00f6ller PC, Motsei M, Muula G, Evans D, Neuenschwander S, G\u00fcnther G, Bolton C, Keller PM, Ramette A, Egger M, Omar SV, Fenner L, IeDEA Southern Africa (2025) Field evaluation of nanopore targeted next-generation sequencing to predict drug-resistant tuberculosis from native sputum in South Africa and Zambia. J Clin Microbiol 63(3):e0139024. https:\/\/doi.org\/10.1128\/jcm.01390-24","journal-title":"J Clin Microbiol"},{"issue":"1","key":"4508_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/13993003.congress-2024.PA639","volume":"70","author":"AV Singh","year":"2024","unstructured":"Singh AV, Kumar R, Yadav R, Chauhan DS, Kumar S (2024) Emergence of bedaquiline resistance among clinical isolates of multi-drug resistant Mycobacterium tuberculosis from Northern part of India. Indian J Tuberc 70(1):1\u20136. https:\/\/doi.org\/10.1183\/13993003.congress-2024.PA639","journal-title":"Indian J Tuberc"},{"key":"4508_CR45","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.2147\/DDDT.S281639","volume":"15","author":"SL Stancil","year":"2021","unstructured":"Stancil SL, Mirzayev F, Abdel-Rahman SM (2021) Profiling pretomanid as a therapeutic option for TB infection: evidence to date. Drug des Devel Ther 15:2815\u20132830. https:\/\/doi.org\/10.2147\/DDDT.S281639","journal-title":"Drug des Devel Ther"},{"issue":"6789","key":"4508_CR46","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/35016103","volume":"405","author":"CK Stover","year":"2000","unstructured":"Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405(6789):962\u2013966. https:\/\/doi.org\/10.1038\/35016103","journal-title":"Nature"},{"issue":"2","key":"4508_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5588\/ijtldopen.24.0360","volume":"2","author":"HTT Thuy","year":"2025","unstructured":"Thuy HTT, Padmapriyadarsini C, Chuchottaworn C, Foraida S, Hadigal S, Birajdar AR (2025) Efficacy and safety data on pretomanid for drug-resistant TB. IJTLD Open 2(2):73\u201382. https:\/\/doi.org\/10.5588\/ijtldopen.24.0360","journal-title":"IJTLD Open"},{"issue":"10","key":"4508_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0002283","volume":"3","author":"J Timm","year":"2023","unstructured":"Timm J, Bateson A, Solanki P, Paleckyte A, Witney AA, Rofael SA, Hunt R, McHugh TD, Lipman M (2023) Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid. PLOS Global Public Health 3(10):e0002283. https:\/\/doi.org\/10.1371\/journal.pgph.0002283","journal-title":"PLOS Global Public Health"},{"issue":"6","key":"4508_CR49","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1128\/AAC.49.6.2289-2293.2005","volume":"49","author":"S Tyagi","year":"2005","unstructured":"Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J (2005) Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 49(6):2289\u20132293. https:\/\/doi.org\/10.1128\/AAC.49.6.2289-2293.2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4508_CR50","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1186\/s13063-022-06793-w","volume":"23","author":"A Van Rie","year":"2022","unstructured":"Van Rie A, De Vos E, Costa E, Verboven L, Ndebele F, Heupink TH, Abrams S, Fanampe B, der Spoel Van, Van Dyk A, Charalambous S, Churchyard G, Warren R, SMARTT team (2022) Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial. Trials 23(1):864. https:\/\/doi.org\/10.1186\/s13063-022-06793-w","journal-title":"Trials"},{"key":"4508_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103690","volume":"75","author":"N Verma","year":"2022","unstructured":"Verma N, Arora V, Awasthi R, Chan Y, Jha NK, Thapa K, Chellappan DK, Dua K, Singh SK (2022) Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis. J Drug Deliv Sci Technol 75:103690. https:\/\/doi.org\/10.1016\/j.jddst.2022.103690","journal-title":"J Drug Deliv Sci Technol"},{"issue":"3","key":"4508_CR52","doi-asserted-by":"publisher","first-page":"1601719","DOI":"10.1183\/13993003.01719-2016","volume":"49","author":"N Veziris","year":"2017","unstructured":"Veziris N, Bernard C, Guglielmetti L, Le Du D, Marigot-Outtandy D, Jaspard M, Caumes E, Lerat I, Rioux C, Yazdanpanah Y, Lounis N (2017) Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: Lessons not to repeat past errors. Eur Respir J 49(3):1601719. https:\/\/doi.org\/10.1183\/13993003.01719-2016","journal-title":"Eur Respir J"},{"issue":"7","key":"4508_CR53","doi-asserted-by":"publisher","first-page":"e02510","DOI":"10.1128\/AAC.02510-16","volume":"61","author":"C Villellas","year":"2017","unstructured":"Villellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, Andries K (2017) Role of the ddn and fgd1 genes in the susceptibility of Mycobacterium tuberculosis to pretomanid (PA-824). Antimicrob Agents Chemother 61(7):e02510-e2516. https:\/\/doi.org\/10.1128\/AAC.02510-16","journal-title":"Antimicrob Agents Chemother"},{"key":"4508_CR54","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10096-019-03549-4","volume":"38","author":"SA Wen","year":"2019","unstructured":"Wen SA, Jing W, Zhang T, Zong Z, Xue Y, Shang Y, Pang Y, Wang C (2019) Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis 38:1293\u20131296. https:\/\/doi.org\/10.1007\/s10096-019-03549-4","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"8","key":"4508_CR55","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1128\/AAC.02632-12","volume":"57","author":"H Winter","year":"2013","unstructured":"Winter H, Egizi E, Erondu N, Ginsberg A, Rouse DJ, Severynse-Stevens D, Pauli E (2013) Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects. Antimicrob Agents Chemother 57(8):3699\u20133703. https:\/\/doi.org\/10.1128\/AAC.02632-12","journal-title":"Antimicrob Agents Chemother"},{"key":"4508_CR56","unstructured":"World Health Organization. (2022). WHO operational handbook on tuberculosis. Module 4: Treatment \u2013 drug-resistant tuberculosis treatment. WHO."},{"key":"4508_CR57","unstructured":"World Health Organization. (2024). Global tuberculosis report 2024. https:\/\/www.who.int\/tb\/publications\/global_report\/en\/"},{"issue":"5","key":"4508_CR58","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00021-19","volume":"63","author":"J Xu","year":"2019","unstructured":"Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Nuermberger E (2019) Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis. Antimicrob Agents Chemother 63(5):e00021\u201319. https:\/\/doi.org\/10.1128\/AAC.00021-19","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"4508_CR59","doi-asserted-by":"publisher","first-page":"820","DOI":"10.21037\/jtd.2018.04.33","volume":"10","author":"M Ye","year":"2018","unstructured":"Ye M, Li S, Huang W, Wang C, Liu L, Liu J, Liu J, Pan H, Deng Q, Tang H, Jiang L (2018) Comprehensive targeted super-deep next generation sequencing enhances differential diagnosis of solitary pulmonary nodules. J Thoracic Dis 10(7):820\u2013829. https:\/\/doi.org\/10.21037\/jtd.2018.04.33","journal-title":"J Thoracic Dis"},{"issue":"1","key":"4508_CR60","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12941-024-00693-4","volume":"23","author":"B Zhao","year":"2024","unstructured":"Zhao B, Zheng H, Timm J, Song Z, Pei S, Xing R, Zhang Z (2024) Prevalence and genetic basis of Mycobacterium tuberculosis resistance to pretomanid in China. Ann Clin Microbiol Antimicrob 23(1):40. https:\/\/doi.org\/10.1186\/s12941-024-00693-4","journal-title":"Ann Clin Microbiol Antimicrob"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-025-04508-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-025-04508-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-025-04508-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:05:55Z","timestamp":1771272355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-025-04508-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4508"],"URL":"https:\/\/doi.org\/10.1007\/s00203-025-04508-8","relation":{},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"35"}}